Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis

Neurology. 2019 Apr 16;92(16):765-767. doi: 10.1212/WNL.0000000000007312. Epub 2019 Mar 20.

Authors

Helen Hayward-Koennecke¹, Markus Reindl², Roland Martin², Sven Schippling²

Affiliations

¹ From Neuroimmunology and MS Research, Neurology Clinic (H.H.-K., R.M., S.S.), University Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria. helen.hayward-koennecke@usz.ch.
² From Neuroimmunology and MS Research, Neurology Clinic (H.H.-K., R.M., S.S.), University Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.

PMID: 30894449
DOI: 10.1212/WNL.0000000000007312

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Autoantibodies / blood*
Humans
Immunologic Factors / therapeutic use*
Male
Middle Aged
Myelin-Oligodendrocyte Glycoprotein / immunology*
Optic Neuritis / diagnostic imaging
Optic Neuritis / immunology*
Optic Neuritis / therapy*
Recurrence

Substances

Antibodies, Monoclonal, Humanized
Autoantibodies
Immunologic Factors
Myelin-Oligodendrocyte Glycoprotein
tocilizumab